Day 3, Thursday, March 20th, 2025Thursday, 20 March 2025 - ET (Eastern Time, GMT-05:00)

The pricing of rare disease therapies has become increasingly complex and controversial. Unpack the factors shaping the evolving pricing landscape, including the impact of patient access initiatives, payer pressures and the role of value-based pricing models.

• Take a practical look at AI and ML to understand how to best tap into its potential whilst also remaining cautious of its pitfalls
• Learn how AI can play a key role in treatment commercialization (i.e., accelerated drug discovery, patient identification and recruitment, patient engagement, etc.)
• Understand how, in the near term, AI will radically change how we look at disease and what could prevent it from being most helpful
• Explore how AI can empower respective stakeholders, including advocates, caregivers and physicians

During this session, uncover Coalition for Clinical Trial Equity’s groundbreaking initiatives in fostering a more equitable and inclusive environment within the Rare Disease landscape. Discover how the Coalition has been instrumental in bridging the diversity gap to advance health equity. Specific initiatives include clinical trial time off/compensation, FMLA legislation and learn about the Alliance to Cure Cavernous Malformations and the Foundation for Sarcoidosis Research are driving on the ground change.

Baptist Health’s new dashboard was created to address the challenges associated with Rare Disease patient identification and diagnosis. Striving to give HCPs and manufacturers greater insight into their patients care journey, unpack the life changing data they are utilizing to create this framework and best in class model.

Alongside key stakeholders, engage in conversation on how innovative digital platforms and strategies are transforming patient access. Uncover the future of digital solutions for payers and providers to optimize the patient journey.

With the election behind us and a new administration in place, the impact on healthcare legislation and regulatory priorities is coming into focus. This session examines key policy shifts, congressional dynamics and the evolving relationship between government and the life sciences sector.

• Assess how the new administration’s priorities and congressional leadership changes are shaping healthcare policies, including drug pricing, market access, and patient assistance programs.
• Examine the increasing trend of industry leaders being called to testify before Congress—will this continue, and what are the implications for pharma and patient access programs?
• Gain strategic insights into navigating the evolving political landscape, preparing for potential legislative changes and engaging effectively with policymakers